BioCentury | Jun 30, 2020
Product Development

Second death in Audentes gene therapy trial may highlight need for more careful dosing

The report of a second patient death in a trial of an AAV8-based gene therapy from Audentes and Astellas renewed decades-old concerns over the modality’s safety, but the adverse events may reflect a need for...
BioCentury | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

Novartis, Microsoft partner on AI for drug R&D Novartis AG (NYSE:NVS; SIX:NOVN) is partnering with Microsoft Corp. (NASDAQ:MSFT) to use artificial intelligence for drug development, with an initial focus on personalized macular degeneration therapies, cell...
BioCentury | Mar 4, 2019
Company News

Biogen to acquire ophthalmology gene therapy play Nightstar

Gene therapy platforms continue to capture the interest of large biopharma, with Biogen the latest to announce a deal. The bellwether said early Monday that it will acquire ophthalmology gene therapy company Nightstar for $877...
BioCentury | Dec 14, 2018
Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Dec. 12 that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was...
BioCentury | Dec 13, 2018
Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Wednesday that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was down...
BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

...acquisitions in the 2x EBITDA range. Companies and Institutions Mentioned Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Applied Genetics...
BioCentury | Jan 19, 2018
Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters...
BioCentury | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

Anti-aging company Unity Biotechnology Inc. (San Francisco, Calif.) hired Bob Goeltz as CFO, Doug Rich as SVP of operations and Tamara Tompkins as general counsel. Goeltz will replace interim CFO John Smither, and Tompkins will...
BioCentury | Sep 19, 2017
Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
BioCentury | Sep 1, 2017
Company News

AGTC and the FFB partner to advance opthalmic research

Applied Genetics Technology Corp. (NASDAQ:AGTC) provided The Foundation Fighting Blindness Inc. (Columbia, Md.) an undisclosed grant which the foundation will use to fund its My Retina Tracker registry as well as a study to determine...
Items per page:
1 - 10 of 145
BioCentury | Jun 30, 2020
Product Development

Second death in Audentes gene therapy trial may highlight need for more careful dosing

The report of a second patient death in a trial of an AAV8-based gene therapy from Audentes and Astellas renewed decades-old concerns over the modality’s safety, but the adverse events may reflect a need for...
BioCentury | Oct 1, 2019
Company News

Oct. 1 Company Quick Takes: NVS, Microsoft to use AI for drug R&D; plus AstraZeneca, Tmunity-CHOP and AGTC-Otonomy deals

Novartis, Microsoft partner on AI for drug R&D Novartis AG (NYSE:NVS; SIX:NOVN) is partnering with Microsoft Corp. (NASDAQ:MSFT) to use artificial intelligence for drug development, with an initial focus on personalized macular degeneration therapies, cell...
BioCentury | Mar 4, 2019
Company News

Biogen to acquire ophthalmology gene therapy play Nightstar

Gene therapy platforms continue to capture the interest of large biopharma, with Biogen the latest to announce a deal. The bellwether said early Monday that it will acquire ophthalmology gene therapy company Nightstar for $877...
BioCentury | Dec 14, 2018
Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Dec. 12 that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was...
BioCentury | Dec 13, 2018
Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Wednesday that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was down...
BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

...acquisitions in the 2x EBITDA range. Companies and Institutions Mentioned Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Applied Genetics...
BioCentury | Jan 19, 2018
Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters...
BioCentury | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

Anti-aging company Unity Biotechnology Inc. (San Francisco, Calif.) hired Bob Goeltz as CFO, Doug Rich as SVP of operations and Tamara Tompkins as general counsel. Goeltz will replace interim CFO John Smither, and Tompkins will...
BioCentury | Sep 19, 2017
Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
BioCentury | Sep 1, 2017
Company News

AGTC and the FFB partner to advance opthalmic research

Applied Genetics Technology Corp. (NASDAQ:AGTC) provided The Foundation Fighting Blindness Inc. (Columbia, Md.) an undisclosed grant which the foundation will use to fund its My Retina Tracker registry as well as a study to determine...
Items per page:
1 - 10 of 145